Ken Griffin Tcr2 Therapeutics Inc. Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.83 - $1.44 $34,630 - $60,081	41,723 Added 21.71%	233,876 $233,000
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $307,028 - $619,008	-165,069 Reduced 46.21%	192,153 $346,000
Q2 2022 Aug 15, 2022	BUY	$2.11 - $2.94 $83,214 - $115,947	39,438 Added 12.41%	357,222 $1.04 Million
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $472,120 - $926,537	-196,717 Reduced 38.23%	317,784 $877,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $638,873 - $1.16 Million	139,492 Added 37.2%	514,501 $2.4 Million

Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $42,090 - $91,511	-4,987 Reduced 1.31%	375,009 $3.19 Million
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $3.44 Million - $5.18 Million	-209,555 Reduced 35.54%	379,996 $6.24 Million
Q1 2021 May 17, 2021	SELL	$20.38 - $34.07 $10.1 Million - $16.9 Million	-495,417 Reduced 45.66%	589,551 $13 Million
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $20.1 Million - $34.6 Million	1,059,386 Added 4141.14%	1,084,968 $33.6 Million
Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $335,124 - $529,291	25,582 New	25,582 $520,000
Q2 2020 Aug 14, 2020	SELL	$6.51 - $16.85 $111,171 - $287,747	-17,077 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$6.01 - $16.01 $102,632 - $273,402	17,077 New	17,077 $132,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.